PMID- 24547916
OWN - NLM
STAT- MEDLINE
DCOM- 20141010
LR  - 20140219
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 13
IP  - 3
DP  - 2014 Mar
TI  - Safety of direct-acting antivirals in the treatment of chronic hepatitis C.
PG  - 307-19
LID - 10.1517/14740338.2014.884068 [doi]
AB  - INTRODUCTION: Combination therapy with pegylated interferon, ribavirin and the 
      two first-generation NS3/4A protease inhibitors (PIs), telaprevir (TVR) and 
      boceprevir (BOC), is the new standard-of-care therapy for patients who are 
      chronically infected with genotype 1 hepatitis C virus. These combinations 
      significantly increase sustained virological response (SVR) rates, but they also 
      increase the rates of adverse events (AEs). Appearance of significant AEs may 
      necessitate dose reduction or discontinuation of treatment, and may impact on 
      virological response. AREAS COVERED: In registration trials, IFN-related AEs were 
      a dominant feature in both types of therapy. Some events were more frequent with 
      PI-containing regimens, like anemia and dysgeusia with BOC and anemia, pruritus, 
      rash and anorectal symptoms with TVR. This review addresses the early 
      identification and management of AEs to improve tolerance, and to avoid reduction 
      in SVR rates. EXPERT OPINION: Every patient will experience adverse effects to 
      differing degrees; a systematic approach to their management can be very helpful. 
      Early recognition and intervention can help clinicians ensure that patients are 
      able to complete therapy where possible and achieve the goal of viral 
      eradication. Treatment with the next generation of antivirals will improve safety 
      and efficacy.
FAU - Ridruejo, Ezequiel
AU  - Ridruejo E
AD  - Centro de Educacion Medica e Investigaciones Clinicas Norberto Quirno "CEMIC", 
      Department of Medicine, Hepatology Section , Avda. Las Heras 2939, (C1425ASG) 
      Ciudad Autonoma de Buenos Aires , Argentina +54 11 5299 1221 ; +54 11 5299 0600 
      ext 5900 ; eridruejo@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20140206
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon-alpha)
RN  - 0 (Protease Inhibitors)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Antiviral Agents/*adverse effects/*therapeutic use
MH  - Drug Therapy, Combination/*adverse effects/methods
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Hepatitis C, Chronic/*drug therapy
MH  - Humans
MH  - Interferon-alpha/adverse effects/therapeutic use
MH  - Protease Inhibitors/adverse effects/therapeutic use
MH  - Ribavirin/adverse effects/therapeutic use
EDAT- 2014/02/20 06:00
MHDA- 2014/10/11 06:00
CRDT- 2014/02/20 06:00
PHST- 2014/02/20 06:00 [entrez]
PHST- 2014/02/20 06:00 [pubmed]
PHST- 2014/10/11 06:00 [medline]
AID - 10.1517/14740338.2014.884068 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2014 Mar;13(3):307-19. doi: 10.1517/14740338.2014.884068. 
      Epub 2014 Feb 6.